Clinical trials: Cirrhosis Liver
Primary Biliary Cholangitis
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
This study is a placebo-controlled, randomized, double-blind, multicenter, parallel-group comparison study in primary biliary cholangitis participants inadequately responding to ursodeoxycholic acid.
- Trial name
- NCT03092765
- Testing
- E6011
- Where
- 46 sites in Japan
- Volunteers
- 29 people
- Sponsor
- EA Pharma Co., Ltd.
Liver Cirrhosis
Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites
Multicentre, open, randomised, and controlled trial conducted in patients diagnosed with recurrent/refractory ascites who meet inclusion/exclusion criteria.
- Trial name
- NCT02612519
- Testing
- Alfapump, TIPS
- Where
- 3 sites in Germany
- Volunteers
- 15 people
- Sponsor
- University of Leipzig
Alcohol Drinking, Cirrhosis
Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in France
Baclofen is an agonist of the amino-butyricum B (GABA-B) receptor used for a long time in neurology to treat spastic contracture.
- Conditions
- Alcohol Drinking, Cirrhosis, Alcohol Withdrawal
- Trial name
- OBADE (NCT02835365)
- Where
- 8 sites in France
- Volunteers
- 218 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
PBC
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
This is a Phase III, randomized, double-blind, multicentre study assessing the efficacy and safety of obecholic acid and Ursodeoxycholic Acid(UDCA) compared with placebo and UDCA in treating of primary biliary cirrhosis (PBC) in…
- Trial name
- NCT06715319
- Testing
- OCA, UDCA
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Inpatient With End Stage Liver Disease
Is Access to Liver Transplantation Similar in Alcoholic or Not Patients?
The purpose of this study is to determine whether there are reasons other than medical reasons that could limit access to liver transplantation in alcoholic patients.
- Trial name
- TRANSALC (NCT01820819)
- Where
- France
- Volunteers
- 574 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C Virus Infection
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
The purpose of the study is to investigate the efficacy and safety of 12 weeks of simeprevir (150 mg qd) in combination with sofosbuvir (400 mg qd) in chronic hepatitis C virus (HCV) genotype 1 infected men and women with…
- Trial name
- NCT02114151
- Testing
- Simeprevir, Sofosbuvir
- Where
- 34 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Janssen Infectious Diseases BVBA
Cirrhosis
Study of the Impact of HYPOglycaemia on Sarcopenia in CIRrhosis
Fasting blood glucose is maintained by hepatic production of glucose from glycogenolysis or gluconeogenesis. In cirrhosis, glycogen storage capacity is reduced, with a consequent increase in gluconeogenesis to maintain blood…
- Trial name
- HYPOCIR (NCT06948656)
- Testing
- fitting a blood glucose sensor, food collection, tests and questionnaires
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Liver Fibrosis
A Potential Novel Marker for Liver Fibrosis in NASH: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor
Soluble secreted proteins that are expressed uniquely in specific organs and whose formation of secretion is regulated by disease states are excellent markers for the disease.
- Trial name
- NCT00941902
- Where
- Israel
- Volunteers
- 148 people
- Sponsor
- Ziv Hospital
Cirrhosis
Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents
Coated stents with different diameters are presently commercially available, but clinical studies on the assessment of the best stent diameter for a better clinical efficacy, a reduced number of complications, and an effective…
- Trial name
- NCT00401895
- Testing
- TIPS created with 8 or 10 mm covered stent
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- University of Roma La Sapienza
Acute Variceal Bleeding, Cirrhosis
Albumin in Acute Variceal Bleeding
The objective of this randomized control clinical trial is to learn the role of albumin in patients with acute variceal bleed. The trial will include all adult patients with acute variceal bleeding and cirrhosis presenting to…
- Trial name
- ALB-AVB (NCT07395141)
- Testing
- Albumin
- Where
- India
- Volunteers
- 60 people
- Sponsor
- King George's Medical University
Hepatitis B, HIV
French HIV-HBV Cohort
The overarching purpose of this study is to further understand the reasons for and clinical implications of persistent HBV infection in patients co-infected with HIV and HBV in the era of highly effective antiviral treatment…
- Conditions
- Hepatitis B, HIV, Liver Cirrhosis, End Stage Liver Disease
- Trial name
- COVViB (NCT02889094)
- Testing
- Routine care
- Where
- 4 sites in France
- Volunteers
- 152 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Hepatitis B, Chronic
Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)
The purpose of this study is to confirm efficacy and safety when administering lamivudine tablet alone in subjects with hepatitis B virus-induced liver cirrhosis.
- Trial name
- NCT01376154
- Testing
- Lamivudine
- Volunteers
- 342 people
- Sponsor
- GlaxoSmithKline
NAFLD, NASH
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis
- Trial name
- FRAMES (NCT04925362)
- Testing
- Biological specimens, Additional visit
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Spontanous Fungal Peritonitis
Risk Factors of Spontaneous Fungal Peritonitis in Cirrhotic Patients
Spontaneous bacterial peritonitis (SBP) is an infection of the peritoneal cavity with no surgically treatable intra-abdominal source of infection.
- Trial name
- NCT05117073
- Testing
- ASCITIC FLUID CULTURE
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Cirrhosis Portal
EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.
The aim of the current study is to assess if EUS-PPGM could predict the treatment response and outcomes of varices to endoscopic variceal ligation (EVL) in patients with chronic hepatitis.
- Trial name
- NCT05597488
- Testing
- EUS guided portal pressure gradient measurement
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese University of Hong Kong
Liver Cirrhoses, Hepatocellular Carcinoma (HCC)
A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease.
- Conditions
- Liver Cirrhoses, Hepatocellular Carcinoma (HCC), Sarcopenia in Liver Cirrhosis, Portal Hypertension Related to Cirrhosis
- Trial name
- DETECT-HCC (NCT07291141)
- Where
- Sweden
- Volunteers
- 600 people
- Sponsor
- Mattias Ekstedt
Acute on Chronic Liver Failure, Cirrhosis
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography
Patients of acute \& chronic liver failure have long been assumed to have coagulopathy \& are given blood products prophylactically as well as during various interventions.
- Trial name
- NCT02757170
- Testing
- Thromboelastography
- Where
- India
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
This is a prospective, open-label, single-arm phase II study designed to evaluate the efficacy and safety of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) in combination with donafenib and pucotenlimab as first-line…
- Trial name
- NCT07353827
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Donafenib, Pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Cirrhosis
Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia.
- Trial name
- NCT02190357
- Testing
- Rifaximin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Changzheng Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.